Aeglea BioTherapeutics presented 20-dose data on 14 patients from the company's completed Phase 1/2 trial and ongoing Phase 2 open-label extension, or OLE, trial for pegzilarginase in patients with
Arginase 1 Deficiency, or ARG1-D, at the Symposium of the Society for the Study of Inborn Errors of Metabolism, or SSIEM.
Aeglea Bio Therapeutics Inc (NASDAQ: AGLE): Phase 1/2, 20-week repeat dose data for pegzilarginase in
arginase 1 deficiency (Sept.
ENPNewswire-August 30, 2019--Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with
Arginase 1 Deficiency at 2019 SSIEM Symposium
Newer immunomarkers of hepatocellular Differentiation, such as
arginase 1 and glypican 3, have been successfully used in hepatoid carcinoma of other organs (pancreas, adrenal, lung, and stomach).
Arginase is an important enzyme that catalyzes the conversion of arginine to ornithine and urea.
Immunohistochemical pitfalls and the importance of glypican 3 and
arginase in the diagnosis of scirrhous hepato-cellular carcinoma.
During chronic infection, arginase-expressing myeloid-derived suppressor cells and circulating
arginase increased in phase with HBV replication without immunopathology, and thus L-arginine decreased.
High
arginase activity can lower NO level by reducing the substrate for NO synthase.
Increased arginine is a feature of the urea cycle disorder
arginase deficiency, but ornithine, the product of the
arginase reaction, is expected to be low to normal rather than increased as observed in this patient.
A novel and promising therapeutic approach for NSCLC: recombinant human
arginase alone or combined with autophagy inhibitor.
Additionally, the expression of the following four macrophage polarization markers transglutaminase 2 (Tgm2),
arginase 1 (Arg1), chemokine (C-X-C motif) ligand 9 (Cxcl9), and nitric oxide synthase 2 (Nos2) was also assessed (example gating schema in Supplementary Figure 8).